Dyne Therapeutics (DYN) Financials

Dyne Therapeutics logo
$16.70 -0.46 (-2.68%)
Closing price 04:00 PM Eastern
Extended Trading
$16.70 0.00 (0.00%)
As of 04:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Annual Income Statements for Dyne Therapeutics

Annual Income Statements for Dyne Therapeutics

This table shows Dyne Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
-15 -59 -149 -168 -236 -317 -446
Consolidated Net Income / (Loss)
-15 -59 -149 -168 -236 -317 -446
Net Income / (Loss) Continuing Operations
-15 -59 -149 -168 -236 -317 -446
Total Pre-Tax Income
-15 -59 -149 -168 -236 -317 -446
Total Operating Income
-14 -59 -150 -171 -242 -344 -468
Total Gross Profit
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses
14 59 150 171 242 344 468
Selling, General & Admin Expense
2.79 13 29 28 31 62 70
Research & Development Expense
11 45 121 143 211 281 398
Total Other Income / (Expense), net
-1.03 0.11 0.73 2.86 6.23 26 22
Interest Expense
0.00 0.40 - - 0.00 0.00 6.19
Interest & Investment Income
0.29 0.06 0.74 2.92 7.64 27 30
Other Income / (Expense), net
-1.32 0.45 -0.01 -0.05 -1.42 -0.45 -1.70
Basic Earnings per Share
($6.08) ($4.13) ($2.93) ($3.23) ($3.95) ($3.37) ($3.47)
Weighted Average Basic Shares Outstanding
2.44M 14.40M 50.90M 51.98M 59.68M 94.14M 128.44M
Diluted Earnings per Share
($6.08) ($4.13) ($2.93) ($3.23) ($3.95) ($3.37) ($3.47)
Weighted Average Diluted Shares Outstanding
2.44M 14.40M 50.90M 51.98M 59.68M 94.14M 128.44M
Weighted Average Basic & Diluted Shares Outstanding
2.44M 14.40M 50.90M 51.98M 59.68M 94.14M 128.44M

Quarterly Income Statements for Dyne Therapeutics

This table shows Dyne Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders
-66 -65 -97 -90 -115 -111 -108 -112 -121 -179 -194
Consolidated Net Income / (Loss)
-66 -65 -97 -90 -115 -111 -108 -112 -121 -179 -194
Net Income / (Loss) Continuing Operations
-66 -65 -97 -90 -115 -111 -108 -112 -121 -179 -194
Total Pre-Tax Income
-66 -65 -97 -90 -115 -111 -108 -112 -121 -179 -194
Total Operating Income
-69 -72 -106 -97 -122 -116 -114 -116 -125 -182 -197
Total Gross Profit
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Cost of Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Operating Expenses
69 72 106 97 122 116 114 116 125 182 197
Selling, General & Admin Expense
25 9.70 13 15 16 17 17 21 24 29 35
Research & Development Expense
45 62 93 82 106 99 97 95 101 152 162
Total Other Income / (Expense), net
3.51 6.86 8.53 7.57 7.01 4.93 5.85 4.17 4.42 3.11 3.52
Interest Expense
- 0.00 0.00 - 0.00 0.09 2.90 - 4.20 4.60 5.95
Interest & Investment Income
3.00 7.05 9.28 7.59 7.10 6.63 8.48 7.66 8.76 7.79 9.77
Other Income / (Expense), net
0.51 -0.19 -0.74 -0.03 -0.09 -1.60 0.28 -0.29 -0.13 -0.09 -0.30
Basic Earnings per Share
($0.81) ($0.70) ($0.96) ($0.90) ($1.05) ($0.97) ($0.76) ($0.69) ($0.73) ($1.08) ($1.06)
Weighted Average Basic Shares Outstanding
81.04M 92.51M 100.88M 94.14M 109.91M 113.87M 141.81M 128.44M 165.04M 165.45M 181.77M
Diluted Earnings per Share
($0.81) ($0.70) ($0.96) ($0.90) ($1.05) ($0.97) ($0.76) ($0.69) ($0.73) ($1.08) ($1.06)
Weighted Average Diluted Shares Outstanding
81.04M 92.51M 100.88M 94.14M 109.91M 113.87M 141.81M 128.44M 165.04M 165.45M 181.77M
Weighted Average Basic & Diluted Shares Outstanding
81.04M 92.51M 100.88M 94.14M 109.91M 113.87M 141.81M 128.44M 165.04M 165.45M 181.77M

Annual Cash Flow Statements for Dyne Therapeutics

This table details how cash moves in and out of Dyne Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
6.51 288 -100 -29 -51 313 458
Net Cash From Operating Activities
-12 -47 -120 -154 -188 -292 -403
Net Cash From Continuing Operating Activities
-12 -47 -120 -154 -188 -292 -403
Net Income / (Loss) Continuing Operations
-15 -59 -149 -168 -236 -317 -446
Consolidated Net Income / (Loss)
-15 -59 -149 -168 -236 -317 -446
Depreciation Expense
0.27 0.70 1.09 1.68 1.67 1.67 2.05
Amortization Expense
0.00 0.08 2.58 1.28 -1.10 -3.60 -1.84
Non-Cash Adjustments To Reconcile Net Income
1.35 6.14 14 17 21 47 46
Changes in Operating Assets and Liabilities, net
1.41 5.11 12 -5.38 26 -19 -3.40
Net Cash From Investing Activities
-1.65 -46 -138 87 83 -204 -29
Net Cash From Continuing Investing Activities
-1.65 -46 -138 87 83 -204 -29
Purchase of Property, Plant & Equipment
-1.65 -1.16 -3.62 -3.07 -0.73 -2.38 -21
Purchase of Investments
0.00 -45 -237 -121 -44 -317 -181
Sale and/or Maturity of Investments
- 0.00 102 211 128 116 172
Net Cash From Financing Activities
20 381 158 37 54 810 890
Net Cash From Continuing Financing Activities
20 381 158 37 54 810 890
Repayment of Debt
0.00 -10 0.00 - 0.00 0.00 -0.56
Issuance of Debt
0.00 9.94 0.00 - 0.00 0.00 148
Issuance of Common Equity
0.00 246 157 37 52 773 735
Other Financing Activities, net
0.00 -0.42 0.58 0.53 1.95 37 8.00
Cash Interest Paid
0.00 0.33 0.00 - 0.00 0.00 4.34

Quarterly Cash Flow Statements for Dyne Therapeutics

This table details how cash moves in and out of Dyne Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
150 336 -76 -97 37 13 89 320 -140 -77 239
Net Cash From Operating Activities
-79 -55 -75 -84 -106 -95 -91 -112 -145 -130 -177
Net Cash From Continuing Operating Activities
-78 -55 -75 -84 -106 -95 -91 -112 -145 -130 -178
Net Income / (Loss) Continuing Operations
-66 -65 -97 -90 -115 -111 -108 -112 -121 -179 -194
Consolidated Net Income / (Loss)
-66 -65 -97 -90 -115 -111 -108 -112 -121 -179 -194
Depreciation Expense
0.39 0.40 0.44 0.45 0.50 0.50 0.52 0.52 0.55 0.56 0.64
Amortization Expense
- -1.27 -0.98 -0.84 -0.62 -0.46 -0.37 -0.39 - - -0.23
Non-Cash Adjustments To Reconcile Net Income
20 6.86 8.88 11 13 10 11 11 13 15 16
Changes in Operating Assets and Liabilities, net
-33 4.24 14 -5.09 -3.60 5.64 5.87 -11 -38 33 -0.94
Net Cash From Investing Activities
-180 11 -19 -16 1.46 6.77 -38 0.98 -2.39 -4.80 -1.29
Net Cash From Continuing Investing Activities
-182 11 -19 -16 1.46 6.77 -38 0.98 -2.39 -4.80 -1.29
Purchase of Property, Plant & Equipment
-0.19 -0.86 -0.25 -1.08 -0.98 -0.06 -19 -0.48 -0.22 -1.51 -2.01
Purchase of Investments
-181 -26 -57 -53 -66 -41 -47 -27 -64 -43 -52
Sale and/or Maturity of Investments
0.00 38 38 38 68 48 28 28 62 40 52
Net Cash From Financing Activities
408 380 18 3.64 141 101 217 431 7.06 58 418
Net Cash From Continuing Financing Activities
408 380 18 3.64 141 101 217 431 7.06 58 418
Repayment of Debt
- - - - 0.00 - - -0.01 -0.03 - -0.06
Issuance of Common Equity
74 376 - - 141 - 216 378 -0.42 - 405
Other Financing Activities, net
11 4.28 18 3.64 0.59 1.97 2.07 3.37 7.52 8.66 13
Cash Interest Paid
- - - - 0.00 - - 2.52 3.63 7.83 1.13

Annual Balance Sheets for Dyne Therapeutics

This table presents Dyne Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
16 353 426 306 165 691 1,187
Total Current Assets
15 349 382 266 129 659 1,127
Cash & Equivalents
15 301 201 172 122 435 893
Short-Term Investments
0.00 44 176 84 1.47 207 217
Prepaid Expenses
0.13 3.77 5.82 9.58 6.28 17 16
Plant, Property, & Equipment, net
1.49 1.95 4.68 5.95 4.78 5.40 24
Total Noncurrent Assets
0.19 2.30 39 35 31 27 36
Other Noncurrent Operating Assets
0.19 2.30 39 35 31 27 36
Total Liabilities & Shareholders' Equity
16 353 426 306 165 691 1,187
Total Liabilities
2.40 11 57 54 74 61 215
Total Current Liabilities
2.36 11 29 28 51 42 51
Accounts Payable
1.26 3.44 4.03 5.26 23 6.56 8.08
Accrued Expenses
1.10 7.53 21 18 23 31 38
Other Current Liabilities
- 0.00 3.89 4.61 4.72 4.85 5.00
Total Noncurrent Liabilities
0.04 0.00 29 26 23 19 164
Long-Term Debt
- - - - - 0.00 149
Capital Lease Obligations
- - - - - - 15
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
14 342 368 252 91 630 972
Total Preferred & Common Equity
14 342 368 252 91 630 972
Preferred Stock
27 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
-13 342 368 252 91 630 972
Common Stock
6.35 422 597 650 724 1,580 2,368
Retained Earnings
-20 -79 -228 -397 -633 -950 -1,396
Accumulated Other Comprehensive Income / (Loss)
0.00 -0.03 -0.27 -0.57 0.00 0.01 0.48

Quarterly Balance Sheets for Dyne Therapeutics

This table presents Dyne Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
251 205 522 826 769 721 729 867 1,080 994 1,235
Total Current Assets
213 168 488 792 736 690 698 806 1,021 938 1,176
Cash & Equivalents
168 130 272 608 532 472 485 574 753 676 913
Short-Term Investments
40 28 182 171 192 205 199 218 219 222 221
Prepaid Expenses
5.44 10 35 13 13 12 14 14 49 39 42
Plant, Property, & Equipment, net
5.36 5.11 4.58 5.02 4.90 5.75 5.68 24 24 25 7.14
Total Noncurrent Assets
33 32 30 29 28 26 23 37 35 32 52
Other Noncurrent Operating Assets
33 32 30 29 28 26 23 37 35 32 52
Total Liabilities & Shareholders' Equity
251 205 522 826 769 721 729 867 1,080 994 1,235
Total Liabilities
45 53 44 51 63 52 158 175 215 292 304
Total Current Liabilities
20 30 22 30 43 34 41 60 51 78 91
Accounts Payable
2.72 3.55 7.21 1.89 6.16 7.02 14 12 11 12 15
Accrued Expenses
13 21 10 23 32 22 22 43 29 46 45
Other Current Liabilities
4.71 4.71 4.76 4.78 4.81 5.11 5.00 5.04 11 20 31
Total Noncurrent Liabilities
24 24 22 21 20 18 116 115 164 214 213
Long-Term Debt
- - - - - - 99 99 149 199 200
Capital Lease Obligations
24 24 - 21 - 18 - 16 14 15 13
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
207 152 478 775 706 669 571 692 865 702 931
Total Preferred & Common Equity
207 152 478 775 706 669 571 692 865 702 931
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
207 152 478 775 706 669 571 692 865 702 931
Common Stock
713 718 1,176 1,539 1,565 1,734 1,747 1,975 2,382 2,398 2,821
Retained Earnings
-506 -566 -698 -763 -860 -1,065 -1,176 -1,284 -1,517 -1,696 -1,889
Accumulated Other Comprehensive Income / (Loss)
-0.06 -0.01 -0.13 -0.24 0.48 0.24 0.25 0.50 -0.14 -0.35 -1.00

Annual Metrics And Ratios for Dyne Therapeutics

This table displays calculated financial ratios and metrics derived from Dyne Therapeutics' official financial filings.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding
- - - - - - 142,824,687.00
DEI Adjusted Shares Outstanding
- - - - - - 142,824,687.00
DEI Earnings Per Adjusted Shares Outstanding
- - - - - - -3.12
Growth Metrics
- - - - - - -
Profitability Metrics
- - - - - - -
Net Operating Profit after Tax (NOPAT)
-9.68 -41 -105 -120 -170 -241 -328
Return On Investment Capital (ROIC_SIMPLE)
- - - -47.42% -185.68% -38.22% -29.23%
Earnings before Interest and Taxes (EBIT)
-15 -58 -150 -171 -244 -344 -470
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-15 -57 -146 -168 -243 -346 -470
Valuation Ratios
- - - - - - -
Leverage & Solvency
- - - - - - -
Liquidity Ratios
- - - - - - -
Cash Flow Metrics
- - - - - - -
Free Cash Flow to Firm (FCFF)
0.00 -39 -100 -124 -141 -260 -351
Efficiency Ratios
- - - - - - -
Capital & Investment Metrics
- - - - - - -
Invested Capital
-0.60 -2.95 -8.37 -3.65 -32 -12 10
Increase / (Decrease) in Invested Capital
0.00 -2.35 -5.43 4.73 -28 19 23
Book Value per Share
($5.48) $7.53 $7.15 $4.86 $1.49 $6.19 $6.81
Tangible Book Value per Share
($5.48) $7.53 $7.15 $4.86 $1.49 $6.19 $6.81
Total Capital
14 342 368 252 91 630 1,121
Total Debt
0.00 0.00 0.00 0.00 0.00 0.00 149
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 149
Net Debt
-15 -345 -377 -256 -123 -642 -962
Capital Expenditures (CapEx)
1.65 1.16 3.62 3.07 0.73 2.38 21
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-2.23 -7.19 -23 -19 -45 -25 -35
Debt-free Net Working Capital (DFNWC)
12 338 354 238 78 617 1,076
Net Working Capital (NWC)
12 338 354 238 78 617 1,076
Net Nonoperating Expense (NNE)
5.18 18 44 48 66 77 118
Net Nonoperating Obligations (NNO)
-15 -345 -377 -256 -123 -642 -962
Total Depreciation and Amortization (D&A)
0.27 0.78 3.67 2.96 0.57 -1.93 0.21
Earnings Adjustments
- - - - - - -
Adjusted Basic Earnings per Share
$0.00 ($4.13) ($2.93) ($3.23) ($3.95) ($3.37) ($3.47)
Adjusted Weighted Average Basic Shares Outstanding
0.00 51.46M 51.64M 56.34M 59.68M 94.14M 128.44M
Adjusted Diluted Earnings per Share
$0.00 ($4.13) ($2.93) ($3.23) ($3.95) ($3.37) ($3.47)
Adjusted Weighted Average Diluted Shares Outstanding
0.00 51.46M 51.64M 51.98M 59.68M 94.14M 128.44M
Adjusted Basic & Diluted Earnings per Share
$0.00 ($4.13) ($2.93) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
0.00 14.40M 50.90M 51.98M 59.68M 94.14M 128.44M
Normalized Net Operating Profit after Tax (NOPAT)
-9.68 -41 -105 -120 -170 -241 -328
Debt Service Ratios
- - - - - - -
Payout Ratios
- - - - - - -

Quarterly Metrics And Ratios for Dyne Therapeutics

This table displays calculated financial ratios and metrics derived from Dyne Therapeutics' official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
- - - - - - - 142,824,687.00 142,824,687.00 142,824,687.00 186,746,431.00
DEI Adjusted Shares Outstanding
- - - - - - - 142,824,687.00 142,824,687.00 142,824,687.00 186,746,431.00
DEI Earnings Per Adjusted Shares Outstanding
- - - - - - - -0.78 -0.85 -1.25 -1.04
Growth Metrics
- - - - - - - - - - -
Revenue Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
EBITDA Growth
-50.20% -8.93% -71.56% -43.02% -79.56% -63.54% -6.19% - -1.86% -54.40% -73.59%
EBIT Growth
-50.29% -7.52% -70.52% -42.03% -78.38% -62.69% -6.87% - -2.41% -54.83% -73.72%
NOPAT Growth
-52.11% -7.83% -69.67% -43.46% -76.95% -60.91% -7.88% - -2.37% -56.89% -73.04%
Net Income Growth
-48.57% -0.31% -61.31% -34.37% -75.72% -70.28% -11.24% - -4.76% -61.07% -79.15%
EPS Growth
-3.85% 35.19% 3.03% 18.18% -29.63% -38.57% 20.83% - 30.48% -11.34% -39.47%
Operating Cash Flow Growth
-67.43% 1.39% -47.48% -140.92% -34.83% -72.60% -21.64% - -36.86% -37.57% -95.52%
Free Cash Flow Firm Growth
-211.13% 41.04% 37.87% -354.44% -2.40% -7.66% -197.57% - -89.89% -238.01% -17.07%
Invested Capital Growth
558.11% -26.31% -202.28% 60.92% -60.42% -193.54% 184.50% - 482.94% 208.25% -35.58%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
EBITDA Q/Q Growth
-0.12% -6.16% -46.44% 8.81% -25.69% 4.26% 3.31% - -7.37% -45.11% -8.70%
EBIT Q/Q Growth
-0.38% -5.10% -47.46% 8.71% -26.07% 4.14% 3.22% - -7.72% -44.93% -8.59%
NOPAT Q/Q Growth
-2.17% -4.06% -46.83% 8.09% -26.02% 5.38% 1.64% - -7.88% -45.01% -8.48%
Net Income Q/Q Growth
1.48% 0.83% -49.19% 7.81% -28.83% 3.90% 2.54% - -7.95% -47.75% -8.40%
EPS Q/Q Growth
26.36% 13.58% -37.14% 6.25% -16.67% 7.62% 21.65% - -5.80% -47.95% 1.85%
Operating Cash Flow Q/Q Growth
-124.35% 30.14% -36.02% -13.01% -25.56% 10.57% 4.14% - -29.59% 10.10% -36.23%
Free Cash Flow Firm Q/Q Growth
-259.97% 36.12% 13.80% -129.28% 18.89% 32.84% -137.85% - -12.59% -19.55% 17.62%
Invested Capital Q/Q Growth
177.05% -29.44% -204.86% 31.45% 178.04% -266.75% 194.73% - 119.41% -69.04% -43.62%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
EBITDA Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Operating Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
EBIT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Profit (Net Income) Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Tax Burden Percent
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% - 100.00% 100.00% 100.00%
Interest Burden Percent
95.63% 90.23% 91.28% 92.18% 94.20% 94.44% 95.10% - 96.37% 98.24% 98.07%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Return on Equity (ROE)
-71.50% -52.46% -68.69% -88.03% -64.01% -61.32% -60.66% - -58.89% -81.57% -74.56%
Cash Return on Invested Capital (CROIC)
-1,465.59% -900.80% 0.00% 0.00% -1,538.60% 0.00% -2,270.67% - -1,137.01% -2,339.11% -3,402.76%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Return on Assets (ROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)
-71.50% -52.46% -68.69% -88.03% -64.01% -61.32% -60.66% - -58.89% -81.57% -74.56%
Return on Equity Simple (ROE_SIMPLE)
-53.84% -33.23% -41.74% 0.00% -54.88% 0.00% 0.00% - 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-48 -50 -74 -68 -86 -81 -80 -81 -88 -127 -138
NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
-4.98% -3.13% -5.40% -5.64% -5.34% -4.43% -4.04% - -4.52% -8.08% -6.96%
Return On Investment Capital (ROIC_SIMPLE)
-10.13% - - -10.79% -12.47% -12.09% -9.88% -7.25% -8.52% -13.88% -12.06%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Operating Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
-69 -72 -106 -97 -122 -117 -114 -116 -125 -182 -197
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-68 -73 -107 -98 -123 -117 -113 -116 -125 -181 -197
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
4.87 3.98 5.11 3.81 1.77 1.89 2.60 - 2.99 5.23 3.23
Price to Tangible Book Value (P/TBV)
4.87 3.98 5.11 3.81 1.77 1.89 2.60 - 2.99 5.23 3.23
Price to Revenue (P/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
76.43 134.50 0.00 0.00 54.02 0.00 73.30 - 31.50 170.77 211.47
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.00 0.03 0.00 0.00 0.03 0.17 0.17 - 0.19 0.30 0.23
Long-Term Debt to Equity
0.00 0.03 0.00 0.00 0.03 0.17 0.17 - 0.19 0.30 0.23
Financial Leverage
-0.96 -0.96 -1.00 -1.06 -0.97 -1.00 -1.00 - -0.96 -1.00 -0.98
Leverage Ratio
1.13 1.10 1.14 1.19 1.08 1.15 1.17 - 1.17 1.35 1.30
Compound Leverage Factor
1.08 0.99 1.04 1.09 1.02 1.09 1.11 - 1.13 1.33 1.27
Debt to Total Capital
0.00% 2.63% 0.00% 0.00% 2.65% 14.74% 14.30% - 15.91% 23.34% 18.64%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 2.63% 0.00% 0.00% 2.65% 14.74% 14.30% - 15.91% 23.34% 18.64%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Common Equity to Total Capital
100.00% 97.37% 100.00% 100.00% 97.35% 85.26% 85.70% - 84.09% 76.66% 81.36%
Debt to EBITDA
0.00 -0.08 0.00 0.00 -0.05 -0.22 -0.26 - -0.35 -0.40 -0.34
Net Debt to EBITDA
0.00 2.78 0.00 0.00 1.66 1.32 1.50 - 1.72 1.28 1.49
Long-Term Debt to EBITDA
0.00 -0.08 0.00 0.00 -0.05 -0.22 -0.26 - -0.35 -0.40 -0.34
Debt to NOPAT
0.00 -0.11 0.00 0.00 -0.07 -0.32 -0.37 - -0.50 -0.57 -0.49
Net Debt to NOPAT
0.00 3.99 0.00 0.00 2.37 1.90 2.15 - 2.45 1.82 2.12
Long-Term Debt to NOPAT
0.00 -0.11 0.00 0.00 -0.07 -0.32 -0.37 - -0.50 -0.57 -0.49
Altman Z-Score
30.33 36.03 33.24 22.11 12.09 2.41 4.69 - 5.96 5.60 4.33
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
21.83 26.63 17.02 15.60 20.35 16.83 13.47 - 19.92 12.02 12.99
Quick Ratio
20.28 26.18 16.73 15.20 20.00 16.49 13.23 - 18.97 11.51 12.53
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-69 -44 -38 -87 -71 -48 -113 -104 -135 -161 -132
Operating Cash Flow to CapEx
-41,118.85% -6,402.33% -29,497.63% -7,845.12% -10,794.39% -157,838.33% -473.18% - -65,575.57% -8,605.42% -8,817.14%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 -506.23 -38.97 - -32.02 -35.00 -22.27
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 -1,007.48 -31.26 - -34.49 -28.35 -29.84
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 -1,008.12 -37.87 - -34.54 -28.68 -30.17
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
25 17 -18 -12 9.70 -16 15 10 57 18 9.87
Invested Capital Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital
21 -6.17 -36 19 -15 -33 33 23 47 34 -5.45
Enterprise Value (EV)
1,873 2,326 2,883 1,755 524 497 1,123 - 1,781 2,990 2,087
Market Capitalization
2,327 3,084 3,606 2,398 1,183 1,082 1,800 - 2,589 3,675 3,008
Book Value per Share
$5.83 $8.87 $7.03 $6.19 $5.91 $5.03 $4.86 $6.81 $5.24 $4.24 $4.99
Tangible Book Value per Share
$5.83 $8.87 $7.03 $6.19 $5.91 $5.03 $4.86 $6.81 $5.24 $4.24 $4.99
Total Capital
478 796 706 630 687 670 807 1,121 1,029 916 1,144
Total Debt
0.00 21 0.00 0.00 18 99 115 149 164 214 213
Total Long-Term Debt
0.00 21 0.00 0.00 18 99 115 149 164 214 213
Net Debt
-454 -758 -724 -642 -659 -585 -676 -962 -809 -685 -921
Capital Expenditures (CapEx)
0.19 0.86 0.25 1.08 0.98 0.06 19 0.48 0.22 1.51 2.01
Debt-free, Cash-free Net Working Capital (DFCFNWC)
12 -16 -31 -25 -22 -27 -45 -35 -2.38 -39 -49
Debt-free Net Working Capital (DFNWC)
466 763 693 617 656 656 746 1,076 970 860 1,085
Net Working Capital (NWC)
466 763 693 617 656 656 746 1,076 970 860 1,085
Net Nonoperating Expense (NNE)
17 15 23 22 30 30 28 31 33 51 56
Net Nonoperating Obligations (NNO)
-454 -758 -724 -642 -659 -588 -676 -962 -809 -685 -921
Total Depreciation and Amortization (D&A)
0.39 -0.87 -0.54 -0.39 -0.11 0.04 0.16 0.13 0.55 0.56 0.41
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($0.81) ($0.70) ($0.96) ($0.90) ($1.05) ($0.97) ($0.76) ($0.69) ($0.73) ($1.08) ($1.06)
Adjusted Weighted Average Basic Shares Outstanding
81.04M 92.51M 100.88M 94.14M 109.91M 113.87M 141.81M 128.44M 165.04M 165.45M 181.77M
Adjusted Diluted Earnings per Share
($0.81) ($0.70) ($0.96) ($0.90) ($1.05) ($0.97) ($0.76) ($0.69) ($0.73) ($1.08) ($1.06)
Adjusted Weighted Average Diluted Shares Outstanding
81.04M 92.51M 100.88M 94.14M 109.91M 113.87M 141.81M 128.44M 165.04M 165.45M 181.77M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
81.04M 92.51M 100.88M 94.14M 109.91M 113.87M 141.81M 128.44M 165.04M 165.45M 181.77M
Normalized Net Operating Profit after Tax (NOPAT)
-48 -50 -74 -68 -86 -81 -80 -81 -88 -127 -138
Normalized NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Pre Tax Income Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 -1,248.81 -39.12 - -29.85 -39.55 -33.18
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 -862.27 -27.45 - -20.87 -27.67 -23.19
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 -1,249.45 -45.73 - -29.90 -39.88 -33.52
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 -862.91 -34.06 - -20.92 -28.00 -23.53
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Dyne Therapeutics remains a development-stage biotechnology company with no reported revenue in the periods provided. Its financial profile is therefore driven by research spending, clinical-development progress, financing activity and the size of its cash reserve rather than sales or operating profits.

  • Strong liquidity position: As of Q2 2026, Dyne held $676.1 million in cash and equivalents plus $222.4 million in short-term investments, or approximately $898.5 million in highly liquid resources. This provides a meaningful financial cushion for ongoing development activities.
  • Substantial equity cushion: Total equity was $702.2 million at the end of Q2 2026, compared with total liabilities of $291.9 million. Although liabilities have increased, the balance sheet remains equity-funded overall.
  • Current assets comfortably exceed current liabilities: Current assets of $937.9 million were roughly 12 times current liabilities of $78.0 million in Q2 2026. This indicates limited near-term liquidity pressure despite the company’s continuing cash burn.
  • Investment income continues to offset part of the operating deficit: Interest and investment income was $7.8 million in Q2 2026. This income stream has generally grown from $1.3 million in Q1 2023 and helps reduce, but does not eliminate, operating losses.

The primary trend is rapid expansion of spending. Quarterly research and development expense increased from $46.7 million in Q2 2022 to $152.2 million in Q2 2026, while selling, general and administrative expense rose from $6.1 million to $29.5 million. Total operating expenses reached $181.7 million in Q2 2026, up from $115.8 million in the restated Q2 2025 results and $125.3 million in Q1 2026.

  • Cash burn remains high but provides a rough runway: Net cash used in operating activities was $130.3 million in Q2 2026, compared with $144.9 million in Q1 2026 and $94.7 million in Q2 2025. Based solely on the Q2 cash-and-investment balance and the latest quarterly operating burn, Dyne has several quarters of liquidity, although the runway will vary with clinical spending, financing and investment activity.
  • Losses are widening: Q2 2026 net loss was $178.6 million, compared with $120.9 million in Q1 2026, $110.9 million in restated Q2 2025 and $65.1 million in restated Q2 2024. The loss per share was negative $1.08 in Q2 2026, versus negative $0.97 in Q2 2025 and negative $0.70 in Q2 2024.
  • The company has not yet generated operating revenue: Reported revenue was zero in each income statement period supplied. With no product revenue to fund operations, Dyne remains dependent on its cash reserves, investment income and external financing.
  • Operating cash flow is consistently negative: Dyne has used cash in operations in every cash-flow period provided. Quarterly operating cash outflow increased from $29.2 million in Q4 2022 to more than $130 million in Q2 2026, reflecting the expanding cost of its research and development programs.
  • Financing dependence and dilution are significant: The company has repeatedly raised capital through equity offerings, including $375.6 million in Q2 2024, $215.8 million in Q3 2025 and $378.2 million in Q4 2025. Weighted-average shares increased from 51.7 million in Q2 2022 to 165.5 million in Q2 2026, creating substantial dilution for existing shareholders.
  • Debt has risen materially: Long-term debt increased from zero reported at the end of Q2 2024 to $199.3 million in Q2 2026, with an additional $14.5 million in capital lease obligations. Q2 2026 financing provided $49.5 million from debt issuance, but interest expense also rose to $4.6 million, adding to the company’s future obligations.

Overall, Dyne’s balance sheet remains well capitalized for a clinical-stage biotechnology company, but its investment case is increasingly dependent on successful development milestones and future financing access. Liquidity is a current strength, while escalating research spending, widening losses, zero revenue and substantial historical dilution remain the most important risks for investors.

11/16/26 05:37 PM ETAI Generated. May Contain Errors.

Dyne Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Dyne Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Dyne Therapeutics' net income appears to be on a downward trend, with a most recent value of -$446.21 million in 2025, falling from -$14.86 million in 2019. The previous period was -$317.42 million in 2024. Check out Dyne Therapeutics' forecast to explore projected trends and price targets.

Dyne Therapeutics' total operating income in 2025 was -$468.18 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $468.18 million

Over the last 6 years, Dyne Therapeutics' total revenue changed from $0.00 in 2019 to $0.00 in 2025, a change of 0.0%.

In the past 13 quarters, Dyne Therapeutics' cash and equivalents has ranged from $130.28 million in Q3 2023 to $913.20 million in Q3 2026, and is currently $913.20 million as of their latest financial filing in Q3 2026.

Dyne Therapeutics had total debt of $148.92 million at the end of 2025, compared with none in 2024, and none in 2019.

Over the last 6 years, Dyne Therapeutics' book value per share changed from -5.48 in 2019 to 6.81 in 2025.



Financial statements for NASDAQ:DYN last updated on 11/5/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners